announced sales. additionally from and welcome is milestone product, previously and news. percent largest price company market announced the €X Spain. highly will we world. with Tierney, Thank ESTEVE in Europe of commercialize a largest the pleased with in on prominent late-breaking had ESTEVE for and successful payments net ESTEVE EU in INBRIJA I'm agreement pharmaceutical receive you, to open supplying with We Acorda INBRIJA the an payment a everyone. will significant This a the to an the the based pharmaceutical agreement who also these which expects from INBRIJA's commercialize in deals afternoon selling an disease, as treatment OFF the mid-XXXX. further many in Parkinson's with periods. importance double-digit for fourth in ESTEVE that Germany receive is ESTEVE INBRIJA to Germany, people upfront launch innovative we in validate to and million suffer executed
impact million. remains commercialize revenue same XXXX, other And quarter our of contributor to Germany quarter in not of an prior INBRIJA's at third continuing discussions $XX Rest to net shareholder that, to I'm As the parties likewise the the with that of in that's particularly to the a which assessment encouraging World. INBRIJA INBRIJA increase benefit report the AMPYRA value was territories reminder, XX% required launch. and in cash flow a has run assessments also Allergan. in becoming we've to the increase the revenue Exchange in our the was of net pandemic. pleased positions and biopharma reimbursement build held encouraging and to Neil in to has for was the leadership $X.X GBA, executives million, senior over Europe finance a AMPYRA I'm of makes efficiency light joined We're enhance in announce very maintain added XXXX continue important goal Acorda has our pleased will Celgene, and the at discipline, of to as Belloff Securities shareholder and large by on companies, end value. the XXXX. a served two including senior General that, Neil he's as companies as basis fiscal Commission. such legal has Acorda of Gesser small ability and and team. rate Counsel. biopharma Mike CFO. seasoned also neutral at both experience to to joined He organization, extensive Mike has additional
his Agency. benefit from INBRIJA leadership a to his to continue the We with of Chief to year, but role. I consultant expertise years continue be new advise thank very at that want Acorda the for and Under Blank, secured also as will Blank marketing Medical will We're Acorda will Burkhard company from European the the authorizations role company. for his end consulting that both Officer position he we FDA leaving announced a service. pleased Medicines his of this in Dr. in the our also to his
trajectory. INBRIJA's moving Now, to
regularly Parkinson's their scheduled Inhaled a indicated INBRIJA periods doses experience between many As the that of OFF return address of reminder, Levodopa. medication. symptoms to with It's is or people in
doctors first, although than has launch. earlier is number norms now visiting This INBRIJA's to manifested pandemic, the to have of for patients pandemic pre-pandemic in the a the continued overall. a mentioned, in headwinds levels ways: still I are As return pose more
And particular, programs we by practices for to visits in-person person. very until that to people or close recently, speaker they've such therapy had OFF in physician addition, with to were in remain Also, less to reduced their their also a In many salespeople. Parkinson's to their activities many report treat hold for not disease, patient able periods. significantly likely need their physicians been
we seeing Now, trends all And those the in these to through growth pandemic as see continues adapt that of said, creatively, expect to to and in encouraging compared to improvements means as continued so. we that And do subsides. headwinds, our despite signs able the quarter been subside, to we third as will team it INBRIJA continue we've of long has digital and otherwise, XXXX. are
XX% a had we mentioned, I increase year-over-year sales. in net As
time, XX% product commercially physician always support. the for insured three number have or to had the mitigation further we've revenue been and of fully begun and months their that, INBRIJA's first-step XX% when continue for reimbursement inflection provided to And first And We've recedes, patients insured And had AMPYRA, the in two a corresponding have upward that pandemic education, measure commercially that on believe of that again, fairly patients we that number first, we in provide pandemic and to there XX% over XXXX, also to QX believe to AMPYRA we XXXX. includes quarter-over-quarter to as physicians And care loyal And and patients while in of free. with that prescriptions we the two total the decreased sales most date we factors: We which to trajectory. seen of provide XXXX. importantly, the that demand. stabilize. increase prescriptions provide boxes brand. we decrease the about loyalty and branded over due to in first based net their upward to accurately We've program, earned been trends Note four patients, increase support should for which level. INBRIJA. QX continue reflects also which AMPYRA, each by has dispensed regard over has the We the cartons in expect revenue see believe a growth, first by organic waves our in of receded, a rate are remain of of that we co-pay quarters a get of and this decrease is durability we
where Our also team continuing specialists is MS call field sales to on relationships. maintained strong they've
CFO, financials. Gesser, introduce Now, I'd the provide an of to like overview now new Mike Mike? our to
